Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Collaborating with Florida International University

Published: Tuesday, February 26, 2013
Last Updated: Tuesday, February 26, 2013
Bookmark and Share
Collaboration to further advance the identification and characterization of designer drugs.

Agilent Technologies Inc. has announced that it is collaborating with Florida International University’s department of chemistry and biochemistry and its International Forensics Research Institute to further advance the identification and characterization of so-called designer drugs.

This work is currently focused on developing and validating new methods for rapid forensic screening and analysis based on advanced chromatography and mass-spectrometry systems such as LC-QQQ-MS/MS, LC-QTOF-MS, GC/MS and GC/MS/MS.

The new methods will expand the capabilities of traditional drug-screening procedures involving immunoassays.

“Since routine immunoassay drug-screening methods are unable to detect most of the hundreds of individual designer drugs that have been identified, we are working with Agilent to develop advanced analytical methods to screen and confirm the presence of such drugs in both ante- and post-mortem specimens,” said Dr. Anthony DeCaprio, associate professor and director of the Forensic & Analytical Toxicology facility at Florida International University’s International Forensic Research Institute.

Dr. DeCaprio continued, “Recently, we validated a method for the detection and quantification of 32 designer drugs in serum, including 24 phenethylamines, four piperazines, and four tryptamines. In collaboration with Agilent, we will continue to expand our tandem mass-spectral library to approximately 300 designer drugs.”

Dr. DeCaprio will present data of interest to forensic scientists and toxicologists in an e-seminar on Tuesday, Feb. 26, as part of a six-seminar series (live and on-demand) at ForensicEd.org.

To learn more about the Florida International University designer drug program, visit “Targeted LC-QQQ MS Screening of Cathinone Derivitaves and Other Designer Drugs in Serum.”

Designer drugs are novel analogs or derivatives of existing illicit drug compounds that are synthesized to circumvent existing laws and to produce similar effects as illegal recreational drugs.

Major classes of designer drugs include phenethylamines, cathinones, tryptamines, piperazines, and synthetic cannabinoids. For years, black-market laboratories could produce and distribute these drugs with little to no threat of prosecution, until last summer when U.S. President Obama signed a bill into law designating certain chemicals found in designer drugs as illegal substances.

Today, as with other illicit drugs already covered under federal law, selling and distributing many specific designer drugs is now prohibited in the United States.

“It is our goal to provide private, academic and government institutions with sophisticated technology and screening methods that will quickly and accurately identify these substances so that laws enacted to restrict their use can be readily enforced,” said Tom Gluodenis, Agilent’s global marketing manager of Forensics and Toxicology.

Gluodenis continued, “We look forward continuing our work with Dr. DeCaprio and his team at Florida International University, and commend them on their ambitious efforts in this important area of research.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies and Ameritox Form Collaboration
Agilent Technologies Inc. and AmeritoxSM announced that they have formed a research collaboration that could accelerate analysis in the field of medication monitoring.
Tuesday, February 12, 2013
Agilent and Johns Hopkins to Research Toxicity Pathways for Embryonic Brain Development Using Metabolomics
The work could help identify possible contributions of chemicals to disorders such as autism and attention hyperactivity disorders.
Friday, August 20, 2010
Agilent and National Institute for Bioprocessing Research and Training, Advance Emerging Glycomics Research
NIBRT's Professor Pauline Rudd has been granted an Agilent Thought Leader Award in support of her emerging glycomics research.
Wednesday, June 30, 2010
Agilent Instruments Selected by South African Doping Control Laboratory for 2010 World Cup
The Company has been selected by as the primary provider of gas-phase testing instruments for the 2010 World Cup.
Wednesday, June 16, 2010
BIOCIUS and Agilent Launch High-throughput, RapidFire® Mass Solution for Drug Discovery
Advanced, integrated system for high quality in vitro ADME analysis unveiled at ASMS Conference, May 23-May 27.
Friday, May 21, 2010
Agilent and the National Center for Food Safety and Technology Collaborate to Develop Food Testing Methods
The collaboration will develop new scientific methods for food testing to solve problems facing global food supply chains.
Wednesday, March 03, 2010
Novel Automated Stem Cell High Content Screening Platform
A new technical poster describes how researchers at I-STEM have used a BioCel 1800 platform for muscular dystrophy therapeutic research.
Friday, June 19, 2009
Agilent Introduces Service to Help GC and LC Labs Demonstrate Test Quality and Calibration
Service leverages expertise in Pharma into chemical, food, flavors, forensics, other labs seeking ISO/IEC 17024-type certification.
Wednesday, June 17, 2009
Agilent Technologies and Anderson Forschung Group Collaborate on Quantitative Protein Assays
The collaboration will combine AFG’s SISCAPA technology with Agilent’s HPLC-Chip and triple quadrupole MS to speed protein biomarker discovery and validation.
Wednesday, June 03, 2009
Agilent Technologies Completes Large-Scale Expansion of Nucleic Acid Manufacturing Capacity
Major expansion enables the company to manufacture several hundred kilograms of therapeutic oligonucleotides per year.
Friday, May 08, 2009
Agilent Technologies Hosts Anti-Doping Agency Officials
The China Anti-Doping Agency to use Agilent instrumentation to confirm the chemical identity of suspected banned substances found in testing samples.
Friday, May 23, 2008
Agilent Technologies Acquires Kalabie Electronic Laboratory Notebook from Klee Group
Agilent expands informatics portfolio with electronic notebook for life sciences, chemical analysis after acquiring Kalabie.
Tuesday, June 19, 2007
Regulators OK Agilent buy of Stratagene
Federal Antitrust Regulators Approve Agilent's Purchase of Stratagene
Monday, May 14, 2007
Agilent Technologies Announces Creation of new Business Unit in Life Sciences and Chemical Analysis
The new business unit will focus on developing a microscopy and optical spectroscopy business that can be leveraged into the electronics, materials testing, life sciences and chemical analysis markets.
Monday, April 02, 2007
Agilent Launches Life Science and Chemical Analysis Centers of Excellence
Demonstration centers highlight Agilent’s full portfolio of life sciences and chemical analysis capabilities.
Tuesday, December 05, 2006
Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!